KIDS Quote, Financials, Valuation and Earnings

The Cooper Companies has a net margin of -20.34% compared to OrthoPediatrics's net margin of 8.75%. OrthoPediatrics's return on equity of -11.21% beat The Cooper Companies's return on equity of 5.15%.

OrthoPediatrics has a consensus price target of $36.43, signalling upside risk potential of 64.84%. On the other hand The Cooper Companies has an analysts' consensus of $94.63 which suggests that it could grow by 32.49%. Given that OrthoPediatrics has higher upside potential than The Cooper Companies, analysts believe OrthoPediatrics is more attractive than The Cooper Companies.

OrthoPediatrics has a beta of 1.084, which suggesting that the stock is 8.356% more volatile than S&P 500. In comparison The Cooper Companies has a beta of 0.979, suggesting its less volatile than the S&P 500 by 2.098%.

OrthoPediatrics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. OrthoPediatrics pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

OrthoPediatrics quarterly revenues are $52.4M, which are smaller than The Cooper Companies quarterly revenues of $1B. OrthoPediatrics's net income of -$10.7M is lower than The Cooper Companies's net income of $87.7M. Notably, OrthoPediatrics's price-to-earnings ratio is -- while The Cooper Companies's PE ratio is 34.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics is 2.41x versus 3.60x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -20.34% compared to OrthoPediatrics's net margin of -391.35%. OrthoPediatrics's return on equity of -11.21% beat Innovative Eyewear's return on equity of -97.69%.

OrthoPediatrics has a consensus price target of $36.43, signalling upside risk potential of 64.84%. On the other hand Innovative Eyewear has an analysts' consensus of $7.00 which suggests that it could grow by 150%. Given that Innovative Eyewear has higher upside potential than OrthoPediatrics, analysts believe Innovative Eyewear is more attractive than OrthoPediatrics.

OrthoPediatrics has a beta of 1.084, which suggesting that the stock is 8.356% more volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OrthoPediatrics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

OrthoPediatrics quarterly revenues are $52.4M, which are larger than Innovative Eyewear quarterly revenues of $454.5K. OrthoPediatrics's net income of -$10.7M is lower than Innovative Eyewear's net income of -$1.8M. Notably, OrthoPediatrics's price-to-earnings ratio is -- while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics is 2.41x versus 3.15x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

NexGel has a net margin of -20.34% compared to OrthoPediatrics's net margin of -25.37%. OrthoPediatrics's return on equity of -11.21% beat NexGel's return on equity of -59.55%.

OrthoPediatrics has a consensus price target of $36.43, signalling upside risk potential of 64.84%. On the other hand NexGel has an analysts' consensus of $6.00 which suggests that it could grow by 151.05%. Given that NexGel has higher upside potential than OrthoPediatrics, analysts believe NexGel is more attractive than OrthoPediatrics.

OrthoPediatrics has a beta of 1.084, which suggesting that the stock is 8.356% more volatile than S&P 500. In comparison NexGel has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OrthoPediatrics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NexGel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics pays -- of its earnings as a dividend. NexGel pays out -- of its earnings as a dividend.

OrthoPediatrics quarterly revenues are $52.4M, which are larger than NexGel quarterly revenues of $2.8M. OrthoPediatrics's net income of -$10.7M is lower than NexGel's net income of -$712K. Notably, OrthoPediatrics's price-to-earnings ratio is -- while NexGel's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics is 2.41x versus 1.62x for NexGel. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -20.34% compared to OrthoPediatrics's net margin of -127.29%. OrthoPediatrics's return on equity of -11.21% beat Staar Surgical's return on equity of -17.97%.

OrthoPediatrics has a consensus price target of $36.43, signalling upside risk potential of 64.84%. On the other hand Staar Surgical has an analysts' consensus of $19.10 which suggests that it could grow by 9.33%. Given that OrthoPediatrics has higher upside potential than Staar Surgical, analysts believe OrthoPediatrics is more attractive than Staar Surgical.

OrthoPediatrics has a beta of 1.084, which suggesting that the stock is 8.356% more volatile than S&P 500. In comparison Staar Surgical has a beta of 0.632, suggesting its less volatile than the S&P 500 by 36.76%.

OrthoPediatrics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OrthoPediatrics pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

OrthoPediatrics quarterly revenues are $52.4M, which are larger than Staar Surgical quarterly revenues of $42.6M. OrthoPediatrics's net income of -$10.7M is higher than Staar Surgical's net income of -$54.2M. Notably, OrthoPediatrics's price-to-earnings ratio is -- while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OrthoPediatrics is 2.41x versus 3.10x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.